Form 4: Topsoe Reports Acquisition of IGM Biosciences Stock Through RSU Vesting

Christina Teng Topsoe, a director of IGM Biosciences, reports acquiring shares through vested restricted stock units and indirect holdings through Topsoe Holding A/S and Pillarcater LLC.

Summary

• Christina Teng Topsoe, a director of IGM Biosciences, filed a Form 4 detailing changes in beneficial ownership.
• On March 31, 2025, Topsoe acquired 1,284 shares of IGM Biosciences common stock through the vesting of restricted stock units (RSUs).
• These RSUs represent a contingent right to receive one share of the Issuer's common stock and are paid as a quarterly retainer under the Outside Director Compensation Policy.
• Vested RSUs will be delivered upon a change in control of the Issuer or the Reporting Person's retirement or separation from service.
• Topsoe also indirectly holds 10,400,564 shares through Topsoe Holding A/S and 9,800 shares through Pillarcater LLC.
• Topsoe disclaims beneficial ownership of the shares held by Topsoe Holding A/S, except to the extent of her pecuniary interest.
• Topsoe is the sole manager of Pillarcater LLC, which is wholly owned by CT Foundation, of which Topsoe is the sole beneficiary.
• Following the reported transaction, Topsoe directly owns 52,951 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects routine director compensation and alignment of interests. There are no indications of negative events or concerns.

Positives

• The acquisition of shares through RSU vesting aligns Topsoe's interests with those of IGM Biosciences shareholders.
• The Outside Director Compensation Policy provides a transparent mechanism for director compensation.

Future Outlook

Vested RSUs will be delivered to the Reporting Person on the earlier of (i) immediately prior to a change in control of the Issuer or (ii) following the Reporting Person's retirement or separation from service with the Issuer.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to the market.

Stakeholder Impact

• The disclosure provides transparency to shareholders regarding director ownership.
• The RSU vesting aligns director interests with shareholder value.

Key Dates

Keywords

IGM Biosciences, Director, Form 4, Beneficial Ownership, RSU, Stock Acquisition, Topsoe, IGMS